Get notified when SCTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Management and auditors have concluded there is substantial doubt about the company's ability to continue as a going concern.
- Material Weakness (new) — The company discloses the risk of material weaknesses in internal controls, which could undermine investor confidence.
- Concentration (new) — The company relies on Acuitas Therapeutics as a single supplier for lipid nanoparticles, a critical component of its delivery technology.
Scribe Therapeutics prices $128.7M IPO at $15/share; concurrent Sanofi placement adds $7.5M
Filed July 27, 2026 · ~2 min read
Key Changes
-
high
Scribe Therapeutics is offering 8,580,000 shares at $15.00 per share, raising $128.7M gross for the company; Sanofi will buy 500,000 shares in a concurrent private placement at the same price.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $122.8M, after underwriting discounts and expenses; proceeds will fund STX-1150 Phase 1, STX-1400 and STX-1200 development, and operations into H1 2029.
Use of Proceeds verify on EDGAR → -
high
The company reported a GAAP net loss of $47.8M for 2024 and $21.8M for 2025; it has an accumulated deficit of $175.1M and no approved products.
Risk Factors verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade SCTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify